- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07288203
Eine Studie zu Lifileucel (tumorinfiltrierenden Lymphozyten) bei Erwachsenen mit fortgeschrittenem Melanom
Eine Phase-2-, multizentrische, offene Studie mit Lifileucel (Tumor-infiltrierende Lymphozyten [TIL]) bei Teilnehmern mit vorbehandeltem fortgeschrittenem Melanom
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor
± a MEK inhibitor
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Queensland
-
Greenslopes, Queensland, Australien, 4120
- Greenslopes Private Hospital
-
-
-
-
Ontario, Canada
-
Toronto, Ontario, Canada, Kanada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec, Canada
-
Montral, Quebec, Canada, Kanada, H2X 0A9
- Centre Hospitalier de l'Universite de Montreal
-
-
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Sarah Cannon Research Institute
-
-
-
-
-
London, Vereinigtes Königreich, SW3 6JJ
- Royal Marsden Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
- The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
- The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
- Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
- Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
- Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- Participants must have adequate organ function.
- Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion Criteria:
- Participant has melanoma of uveal/ocular origin.
- Participant has symptomatic untreated brain metastases.
- Participant has active uveitis that requires active treatment.
- Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
- Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
- Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
- Participant has a history of allogeneic cell or organ transplant.
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Other protocol defined inclusion/exclusion criteria could apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Single Arm
Lifileucel |
A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate
Zeitfenster: 12 months
|
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators |
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete Response Rate
Zeitfenster: 12 months
|
To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Duration of Response
Zeitfenster: 12 months
|
To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Disease Control Rate
Zeitfenster: 12 months
|
To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Progression-Free Survival
Zeitfenster: 12 months
|
To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Overall Survival
Zeitfenster: 18 months
|
To evaluate the efficacy of lifileucel as measured by OS |
18 months
|
|
Adverse Events
Zeitfenster: 18 months
|
To demonstrate safety and tolerability of lifileucel |
18 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IOV-MEL-202
- 2025-522054-40-00 (Ctis)
- 2025 (US NIH Stipendium/Vertrag)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .